Sanofi stock: Q3 growth lifts 2026 outlook
Published on 11/09/2026 at 11:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth And Guidance Set The Tone
- Sanofi delivered strong third-quarter growth led by Dupixent and newer medicines.
- Management raised its full-year sales and business EPS outlook.
- Upcoming investor events keep pipeline execution and long-term growth in focus.
Sanofi reported strong third-quarter momentum on October 30, 2026, with sales growth and higher business earnings per share prompting an upgrade to its full-year outlook. The company's official press release said third-quarter sales rose 14.3% at constant exchange rates to 14.444 billion euros.
Business EPS reached 3.55 euros, up 19.6% at constant exchange rates and 22.0% at actual exchange rates. IFRS EPS was 2.52 euros, while IFRS net income increased 7.8% to 3.021 billion euros. Sanofi's business operating income advanced 19.7% at constant exchange rates, indicating that stronger sales translated into faster growth in the company's adjusted operating result.
Dupixent Remains The Main Growth Engine
Dupixent sales increased 34.8% to 5.7 billion euros and exceeded 5 billion euros for the second consecutive quarter. Pharma launches generated 1.4 billion euros, up 31.4%, driven by ALTUVIIIO, Ayvakit and Rezurock. Vaccine sales declined 6.6% to 3.2 billion euros as respiratory-prevention demand followed the expected seasonal phasing.
Sanofi said the quarter also included two regulatory approvals, one regulatory submission acceptance and two additional regulatory designations. Those milestones add support to the company's effort to broaden its portfolio beyond Dupixent while maintaining momentum in immunology, rare diseases and vaccines.
Higher 2026 Targets Raise The Bar
Management upgraded 2026 guidance to low-teens sales growth and mid-teens business EPS growth, both at constant exchange rates. Chief Executive Officer Belén Garijo attributed the stronger performance to new medicines, Dupixent and cost discipline. The company also said it is preparing for Dupixent's eventual loss of exclusivity by improving research and development productivity and using business development and acquisitions to support its longer-term transformation.
Sanofi stock traded at 85.97 euros on Lang & Schwarz at 11:53 CET on Monday, November 9, 2026. The real-time quote of Sanofi stock provides the latest trading indication.
The company's investor calendar lists the Wolfe Research Healthcare Conference in New York for November 10, 2026, followed by the Jefferies Global Healthcare Conference in London on November 17. These events may keep attention on pipeline progress, commercial execution and the company's post-Dupixent strategy, without changing the financial targets already announced.
Investors can place the French pharmaceutical group in the broader current market reports.
More news and analyses on Sanofi stock cover the company's earnings momentum and outlook.
Sanofi Company Facts
- Company: Sanofi
- ISIN: FR0000120578
- Trading indication: 85.97 euros on Lang & Schwarz, November 9, 2026, 11:53 CET
- Third-quarter sales: 14.444 billion euros, up 14.3% at constant exchange rates
- Business EPS: 3.55 euros, up 19.6% at constant exchange rates
